ProKidney halts one CKD cell therapy phase 3 trial considered surplus to FDA approval

[cafead]

via ProKidney has stopped one of a pair of phase 3 trials for its cell therapy for kidney disease after deciding it wasn’t essential for securing FDA approval.

The product, called rilparencel or REACT, is an autologous cell therapy creating by identifying progenitor cells in a patient’s biopsy.

article source